VEGFA and neoplasm: Pharmacokinetic data revealed that the concentrations of NK012 and free SN-38 after administration of NK012 alone were not significantly different from those obtained for the combination of NK012 plus bevacizumab, suggesting that VEGF-induced angiogenesis inhibition by bevacizumab does not disturb NK012 tumor accumulation and produces an additional antitumor effect by reducing the area of proliferating vascular endothelial cells in the tumors [146].